Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy

Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy Robert C. Kane, Peter F. Bross, Ann T. Farrell, Richard Pazdur Oncologist 2003; 8: 508-513 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in acute and chronic leukemias and multiple myeloma and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Discuss the rationale and requirements for accelerated cancer drug approval by the U.S. Food and Drug Administration (FDA). Identify the current indications for the use of a recently approved agent, bortezomib (Velcade®, PS-341), in the treatment of multiple myeloma. Describe the plans for the further clinical development of this agent as part of accelerated approval by the FDA. Explain the mechanism of action of bortezomib and its role in cancer treatment. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Dec. 03, 2003 Most Recent Review: Dec. 03, 2003* Most Recent Update: Dec. 03, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.